Raw Data F1000.xlsx

Khamira Abresham Hakim Arshadwala (KAHAW), a distinguished,
traditional Unani formulation comprising constituents of herbal, animal, and
mineral origin, holds salubrious cardioprotective potential and has been used
for cardiac ailments in the Unani system for ages. KAHAW is a ‘sugar-based’
preparation, which hinders its ‘claim to fame’ amongst cardiac patients with
diabetes. Hence, it is fascinating to develop a novel nanoformulation of the
traditional one and screen its efficacy experimentally.

To revolutionize this historic gem of a formulation and
enhance its therapeutic efficacy, a novel nanoformulation of KAHAW was
developed, and its cardioprotective potential screened against isoprenaline
(ISO) induced cardiotoxicity in rodents. The results were analyzed with the
traditional formulations and two clinically used drugs, Ramipril and
Carvedilol.

Various parameters viz; Physical, Enzymatic, Non-enzymatic,
and cardiac-specific biomarkers like α/β-MHC expression
(Western Blot), Flow cytometry, Cardiac collagen content, and Mitochondrial enzyme
assay were assessed on plasma, blood, and tissue samples followed by
histomorphological investigations.

The
effect of nanoformulation showed highly significant results (***p<0.001)
when compared to disease control for different parameters viz, Total protein,
GPx and GSH, Lipid peroxidation, and Vitamin E. The cardiac-specific biomarkers like α/β-MHC Expression (Western
Blot), Flow Cytometry, Cardiac collagen content, and Mitochondrial enzyme assay
also advocated the highly significant (***p<0.001) cardioprotective activity
of the developed nanoformulation.

The
research reiterates that the novel nanoformulation offers improved efficacy at
a reduced dose against ISO-induced experimental models of myocardial necrosis.